Biomarkers of progression of chronic obstructive pulmonary disease (COPD). – ScienceOpen
9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Biomarkers of progression of chronic obstructive pulmonary disease (COPD).

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Disease progression of chronic obstructive pulmonary disease (COPD) is variable, with some patients having a relatively stable course, while others suffer relentless progression leading to severe breathlessness, frequent acute exacerbations of COPD (AECOPD), respiratory failure and death. Radiological markers such as CT emphysema index, bronchiectasis and coronary artery calcification (CAC) have been linked with increased mortality in COPD patients. Molecular changes in lung tissue reflect alterations in lung pathology that occur with disease progression; however, lung tissue is not routinely accessible. Cell counts (including neutrophils) and mediators in induced sputum have been associated with lung function and risk of exacerbations. Examples of peripheral blood biological markers (biomarkers) include those associated with lung function (reduced CC-16), emphysema severity (increased adiponectin, reduced sRAGE), exacerbations and mortality [increased CRP, fibrinogen, leukocyte count, IL-6, IL-8, and tumor necrosis factor α (TNF-α)] including increased YKL-40 with mortality. Emerging approaches to discovering markers of gene-environment interaction include exhaled breath analysis [volatile organic compounds (VOCs), exhaled breath condensate], cellular and systemic responses to exposure to air pollution, alterations in the lung microbiome, and biomarkers of lung ageing such as telomere length shortening and reduced levels of sirtuins. Overcoming methodological challenges in sampling and quality control will enable more robust yet easily accessible biomarkers to be developed and qualified, in order to optimise personalised medicine in patients with COPD.

          Related collections

          Author and article information

          Journal
          J Thorac Dis
          Journal of thoracic disease
          2072-1439
          2072-1439
          Nov 2014
          : 6
          : 11
          Affiliations
          [1 ] 1 Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia ; 2 UQ Thoracic Research Centre, School of Medicine, the University of Queensland, Brisbane, Australia.
          Article
          jtd-06-11-1532
          10.3978/j.issn.2072-1439.2014.11.33
          4255159
          25478195
          af1891d7-6680-4c17-beff-c10aee0635ba
          History

          Pulmonary disease,biological markers (biomarkers),blood,chronic obstructive,disease progression,lung,sputum

          Comments

          Comment on this article